Products
Lintuzumab Biosimilar Radiolabelled Antibody (CD33) for Research
Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-314-1mg | 1mg | |
| GMP-Bios-ab-314-10mg | 10mg | |
| GMP-Bios-ab-314-100mg | 100mg | |
| GMP-Bios-ab-314-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody |
| INN Name | Lintuzumab |
| Target | CD33 |
| Format | Whole mAb Radiolabelled |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1996 |
| Year Recommended | 1997 |
| Companies | PDL BioPharma;Seattle Genetics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Acute myeloid leukaemia;Myelodysplastic syndromes |
| Development Tech | na |
About target - CD33
1. Protein Myeloid cell surface antigen CD33
2. Gene CD33
3. Organism Homo sapiens (Human)
Function
Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:15597323, PubMed:11320212).
Preferential ly recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872).
Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109).
These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:10556798, PubMed:10206955, PubMed:10887109).
In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955, PubMed:10887109).
One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323).
